Sponsor or institution
Clinical trials and research at Bioray Laboratories
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Bioray Laboratories that are recruiting, in China. By phase: Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Off-the-shelf BCMA CAR‑T for relapsed or refractory multiple myeloma | — | Shanghai | Recruiting | Nov 25, 2025 |
| Universal CAR-T therapy for CD19-positive B‑cell non-Hodgkin lymphoma | — | Shanghai | Recruiting | Nov 25, 2025 |
| Long-term observation of BHC001 treatment for beta thalassemia | — | Nanning, Guangxi and 1 other locations | Recruiting | Mar 18, 2024 |
| Long-term safety and effectiveness of BRL-101 in transfusion-dependent beta-thalassemia | — | Guangzhou, Guangdong and 6 other locations | Recruiting | Mar 7, 2024 |
| Evaluating BRL-201 for treating relapsed/refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Wuhan, Hubei and 2 other locations | Recruiting | Feb 23, 2023 |
All recruiting trials (5)
-
Off-the-shelf BCMA CAR‑T for relapsed or refractory multiple myeloma
This trial will try a universal (allogeneic) BCMA-directed CAR‑T cell treatment for people with relapsed or refractory multiple myeloma to see if it is safe and can reduce disease.
-
Universal CAR-T therapy for CD19-positive B‑cell non-Hodgkin lymphoma
This study will try an off‑the‑shelf CAR‑T product called BRL‑301 in adults with CD19‑positive B‑cell non‑Hodgkin lymphoma to see if a single 5×10^6/kg dose is safe and shows anti‑tumor activity.
-
Long-term observation of BHC001 treatment for beta thalassemia
This study looks at the long-term safety and effects of a treatment called BHC001 in people with beta thalassemia who need regular blood transfusions.
-
Long-term safety and effectiveness of BRL-101 in transfusion-dependent beta-thalassemia
This study looks at whether BRL-101 remains safe and effective over the long term for people with transfusion-dependent beta-thalassemia.
-
Evaluating BRL-201 for treating relapsed/refractory B-cell Non-Hodgkin Lymphoma
This study is testing a new CAR-T cell therapy called BRL-201 to see if it can help people with relapsed or hard-to-treat B-cell Non-Hodgkin Lymphoma.
Quick answers
How many clinical trials run by Bioray Laboratories are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.